Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5706840 | 0.92 | KCNH2 (0.54) | KCNH2 | |
| SCHEMBL6150702 | 0.92 | MEN1 (0.52) | KCNH2MEN1KMT2AL3MBTL1POLB | |
| Hydrochloric Acid SCHEMBL6147121 | 0.91 | KCNH2 (0.51) | KCNH2MEN1KMT2AL3MBTL1POLB | |
| SCHEMBL6146430 | 0.90 | KCNH2 (0.64) | KCNH2MEN1KMT2AL3MBTL1POLB | |
| SCHEMBL6145864 | 0.88 | KCNH2 (0.49) | KCNH2MEN1KMT2AL3MBTL1POLB | |
| SCHEMBL6145141 | 0.88 | KCNH2 (0.47) | KCNH2MEN1KMT2AL3MBTL1POLB | |
| SCHEMBL6143652 | 0.88 | POLB (0.54) | KCNH2MEN1KMT2AL3MBTL1POLB | |
| SCHEMBL6145246 | 0.88 | KCNH2 (0.47) | KCNH2MEN1KMT2AL3MBTL1POLB | |
| SCHEMBL6144147 | 0.88 | KCNH2 (0.48) | KCNH2MEN1KMT2APOLB | |
| SCHEMBL6145505 | 0.87 | KCNH2 (0.48) | KCNH2MEN1KMT2AL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903217-B2 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. (FR) | 2005-06-07 | — | — | US | disclosed |
| US-20040147518-A1 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. | 2004-07-29 | — | — | US | disclosed |
| US-6603005-B2 | Bactericides | AVENTIS PHARMA S.A. (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020111492-A1 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | NOVEXEL (FR) | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147518-A1 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | SYNJ1, NCAPD2, SYNJ2 | KCNH2 81/4885MEN1 250/4885KMT2A 4202/4885 |
| US-20020111492-A1 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | SYNJ1, NCAPD2, SYNJ2 | KCNH2 81/4885MEN1 250/4885KMT2A 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.